Skip to content
← Non-Hodgkin Lymphoma

FOR PATIENTS · SOURCE READING

Treatment of Indolent Non-Hodgkin Lymphoma

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

For information about the treatments listed below, see the Treatment Option Overview section.

Source links and citations

Treatment of indolent stage I and indolent, contiguous stage II non-Hodgkin lymphoma may include the following:

Source links and citations

Radiation therapy.

Source links and citations

Monoclonal antibody therapy (rituximab) and/or chemotherapy.

Source links and citations

Watchful waiting.

Source links and citations

If the tumor is too large to be treated with radiation therapy, the treatment options for indolent, noncontiguous stage II, III, or IV non-Hodgkin lymphoma will be used.

Source links and citations

Treatment of indolent, noncontiguous stage II, III, or IV non-Hodgkin lymphoma may include the following:

Watchful waiting for patients who do not have signs or symptoms.

Source links and citations

Monoclonal antibody therapy (rituximab) with or without chemotherapy.

Lenalidomide and rituximab.

Source links and citations

Maintenance therapy with rituximab.

Source links and citations

Monoclonal antibody therapy (obinutuzumab) with or without chemotherapy.

Source links and citations

EZH2 inhibitor therapy (tazemetostat).

Source links and citations

Radiolabeled monoclonal antibody therapy.

Source links and citations

A clinical trial of high-dose chemotherapy with or without total-body irradiation or radiolabeled monoclonal antibody therapy, followed by autologous or allogeneic stem cell transplant.

Source links and citations

A clinical trial of chemotherapy with or without vaccine therapy.

Source links and citations

A clinical trial of new types of monoclonal antibodies.

A clinical trial of radiation therapy that includes nearby lymph nodes, for patients who have stage III disease.

Source links and citations

A clinical trial of low-dose radiation therapy, to relieve symptoms and improve quality of life.

Source links and citations

Other treatments for indolent non-Hodgkin lymphoma depend on the type of non-Hodgkin lymphoma. Treatment may include the following:

For follicular lymphoma, treatment may be within a clinical trial of new monoclonal antibody therapy, new chemotherapy regimen, or a stem cell transplant.

Source links and citations

For lymphoplasmacytic lymphoma (Waldenström macroglobulinemia), tyrosine kinase inhibitor therapy and/or plasmapheresis or proteasome inhibitor therapy (if needed to make the blood thinner) is used. Other treatments that are like those used for follicular lymphoma may also be given.

Source links and citations

For gastric mucosa-associated lymphoid tissue (MALT) lymphoma, antibiotic therapy to treat Helicobacter pylori infection is given first. For tumors that do not respond to antibiotic therapy, treatment is radiation therapy, surgery, or rituximab with or without chemotherapy.

Source links and citations

For extragastric MALT lymphoma of the eye and Mediterranean abdominal lymphoma, antibiotic therapy is used to treat infection.

Source links and citations

For splenic marginal zone lymphoma, rituximab with or without chemotherapy and B-cell receptor therapy is used as initial treatment. If the tumor does not respond to treatment, a splenectomy may be done.

Source links and citations

Preserved source evidence · Independent clinical review pending · Not medical advice